Eikon Therapeutics vs Verge Genomics (2026)
Two companies that refused the usual proxies and built different instruments instead. Eikon watches proteins move inside living cells using super resolution microscopy descended from Nobel recognised imaging, producing dynamic measurement nobody else in this category has, with disclosed clinical work in oncology. Verge went all in human, building on a proprietary library of multi omic patient tissue rather than animal models, which targets the specific reason neurology programmes fail, and it has taken a molecule into human study. Both are strong platform arguments and both share the same blind spot: neither publishes whose tissue or which cell lines the platform learned from, and a target discovered in one population is not automatically a target in another.
- The differentiating asset is an instrument, watching individual proteins move inside living cells with super resolution microscopy rather than measuring a static endpoint.
- Regulatory activity is real at the asset level with disclosed clinical work in oncology, and public reporting documents the capital position.
- The platform screens and characterises targets to feed medicinal chemistry rather than claiming to replace it.
- The all in human platform is built on a proprietary library of multi omic patient tissue rather than animal or cell line proxies.
- Deal architecture is unusually well disclosed for a private company, so a partner can see the shape of the relationship before entering it.
- It has taken a molecule through investigational new drug status into human study, which most platforms here have not.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. Eikon Therapeutics and Verge Genomics are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | Eikon Therapeutics | Verge Genomics |
|---|---|---|
| Primary category | Drug Discovery AI | Drug Discovery AI |
| Founded | 2019 | 2015 |
| Headquarters | South San Francisco, CA | South San Francisco, California, United States |
| Website | eikontx.com | vergegenomics.com |
Side by Side
Each record in one paragraph
Written to be quoted whole. Each paragraph states what the AI Health Index verified about the vendor, with the caveats attached. Generated from this pair’s live capability grades, so it moves when a grade moves.
The AI Health Index records no top capability grade for Eikon Therapeutics on any axis it scores. Set against Verge Genomics, Eikon Therapeutics grades higher on Model Supply Chain Disclosure, AI Safety and PHI Stewardship and FDA and Regulatory Status. Its thinnest published disclosure sits on AI Liability and Recourse. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, August 2026
The AI Health Index awards Verge Genomics its top capability grade on AI Centrality. Set against Eikon Therapeutics, Verge Genomics grades higher on several axes, including AI Centrality, Model and Technology Transparency and Clinical and Operational Evidence. Its thinnest published disclosure sits on Model Supply Chain Disclosure. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, August 2026
Questions buyers ask
Should we choose Eikon Therapeutics or Verge Genomics?
On the axes where the AI Health Index separates them, Eikon Therapeutics grades higher on Model Supply Chain Disclosure, AI Safety and PHI Stewardship and FDA and Regulatory Status, and Verge Genomics grades higher on several axes, including AI Centrality, Model and Technology Transparency and Clinical and Operational Evidence. Verge Genomics leads on the greater share of scored axes, but the split means the decision turns on which constraint is binding rather than on an overall winner.
Where do Eikon Therapeutics and Verge Genomics differ most?
The widest separation the AI Health Index records between Eikon Therapeutics and Verge Genomics is on Model Supply Chain Disclosure, where Eikon Therapeutics grades C and Verge Genomics grades D. That axis sits in the AI Capability group, so it should carry the most weight for a buyer whose binding constraint is how much of the work the model itself is trusted to do.
Where do Eikon Therapeutics and Verge Genomics grade the same?
The AI Health Index grades Eikon Therapeutics and Verge Genomics the same on several axes, including Autonomy and Oversight Model, HIPAA and BAA Posture and Security Certifications and Trust Center. Neither holds an advantage the index can evidence on those axes, so they should not carry weight in a selection between these two.
What have Eikon Therapeutics and Verge Genomics not disclosed?
At the last review, at least one of Eikon Therapeutics and Verge Genomics published thin or absent detail on Model Supply Chain Disclosure and AI Liability and Recourse. The AI Health Index treats an absent disclosure as a gap in the public record rather than a failure of the product, so these are the axes to get in writing during diligence instead of inferring from the grade.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Drug Discovery AI page.
Both build on human derived material and neither publishes the demographic composition of the tissue or cell lines behind the platform, which is where the bias question lives for discovery companies that generate their own biology: a target found in one population is not automatically a target in another. Both describe their measurement approach clearly and the computational layer barely at all, which is the shared gap in instrument led discovery. Neither holds a located security attestation.